The European Medicines Agency (EMA) has made a recommendation to use an antibody developed by AstraZeneca to help prevent COVID-19 infection. At a time when Europe is facing an increase in disease rates and the process of vaccinating adults has slowed down, such a drug could be an important alternative.
EMA concluded that Evusheld should be used in adults and adolescents over 12 years of age who have not been exposed to the virus. For comparison: other such drugs from e.g. Regeneron Pharmaceuticals, Eli Lilly and partners Gl...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
